Defective inhibition of dream event memory formation: A hypothesized mechanism in the onset and progression of symptoms of schizophrenia

Brain Research Bulletin

Volumn 46, Issue 3, 1998, Pages 189-197

  Kelly, Peter H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Delusions; Dreams; Memory formation; Schizophrenia; Vasotocin

Indexed keywords

ARGIPRESTOCIN;

DELUSION; DREAMING; HABENULA; HUMAN; MEMORY; PRIORITY JOURNAL; REM SLEEP; REVIEW; SCHIZOPHRENIA;

DELUSIONS; DISEASE PROGRESSION; DREAMS; HUMANS; INHIBITION (PSYCHOLOGY); MEMORY; MODELS, PSYCHOLOGICAL; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0031816347     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(98)00011-2     Document Type: Review

References (146)

1. Acher, R.; Chauvet, J.; Chauvet, M. T. Man and the chimaera: Selective versus neutral oxytocin evolution. In: Ivell, R.; Russell, J., eds. Oxytocin. New York: Plenum Press; 1995:615-627.
2. Ackenheil, M. Clozapine - pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99:S32-S37; 1989.
3. Albeck, D.; Smock, T.; Arnold, S.; Raese, K.; Paynter, K.; Colaprete, S. Peptidergic transmission in the brain. IV. Sex hormone dependence in the vasopressin/oxytocin system. Peptides 12:53-56; 1991.
4. Argiolis, A.; Melis, M. R. Oxytocin-induced penile erection: Role of nitric oxide. In: Ivell, R.; Russell, J., eds. Oxytocin. New York: Plenum Press; 1995:247-254.
5. Arthur, A. Z. Theories and explanations of delusions. Am. J. Psychiat. 121:105-115; 1964.
6. Artman, H. G.; Leake, R. D.; Weitzman, R. E.; Sawyer, W. H.; Fisher, D. A. Radioimmunoassay of vasotocin, vasopressin, and oxytocin in human neonatal cerebrospinal and amniotic fluid. Dev. Pharm. Ther. 7:39-49; 1984.
7. Aserinsky, E.; Kleitman, N. Regularly occurring periods of eye motility and concomitant phenomena during sleep. Science 118:273-274; 1953.
8. Aserinsky, E.; Kleitman, N. Two types of ocular motility occurring in sleep. J. Appl. Physiol. 8:1-10; 1955.
9. Beckmann, B.; Hippius, H.; Ruther, E. Treatment of schizophrenia. Prog. Neuro-Psychopharmacol. 3:47-52; 1979.
10. Benson, B.; Ebels, I.; Hruby, V. J. Isolation and structure elucidation of bovine pineal arginine vasopressin: Arginine vasotocin not identified. Int. J. Pept. Protein Res. 36:109-121; 1990.
11. Benson, B.; Matthews, M. J.; Hadley, M. E.; Powers, S.; Hruby, V. J. Differential localization of antigonadotropic and vasotocic activities in bovine and rat pineal. Life Sci. 19:747-754; 1976.
12. Bleuler, E. Dementia praecox or the group of schizophrenias (English translation; Zinkin, J). New York: International Universities Press; 1950; (original, 1911).
13. Bleuler, M. Conception of schizophrenia within the last fifty years and today. Int. J. Psychiatry 1:501-523; 1965.
14. Bloch, V.; Hennevin, E.; Leconte, P. The phenomenon of paradoxical sleep augmentation after learning: Experimental studies of its characteristics and significance. In: Fishbein, W., ed. Sleep, dreams and memory. Lancaster: MTP Press; 1981:125-133.
15. Bowie, E. P.; Herbert, D. C. Immunocytochemical evidence for the presence of arginine vasotocin in the rat pineal gland. Nature 261:66; 1976.
16. Calev, A. Recall and recognition in chronic nondemented schizophrenics: Use of matched tasks. J. Abnorm. Psychol. 93:172-177; 1984.
17. Calev, A. Recall and recognition in mildly disturbed schizophrenics: The use of matched tasks. Psychol. Med. 14:425-429; 1984.
18. Cheesman, D. W. Structural elucidation of a gonadotropin-inhibiting substance from the bovine pineal gland. Biochim. Biophys. Acta 207:247-253; 1970.
19. Chiodo, L. A.; Bunney, B. S. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3:1607-1619; 1983.
20. Chiodo, L. A.; Bunney, B. S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 5:2539-2544; 1985.
21. Cotes, M.; Crow, T. J.; Johnstone, E. C.; Bartlett, W.; Bourne, R. C. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychol. Med. 8:657-665; 1978.
22. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483; 1976.
23. Crick, F.; Mitchison, G. The function of dream sleep. Nature 304: 111-114; 1983.
24. Crick, F.; Mitchison, G. REM sleep and neural nets. Behav. Brain Res. 69:147-155; 1995.
25. Crow, T. J. A Darwinian approach to the origins of psychosis. Br. J. Psychiatry 167:12-15; erratum 167:414; 1995.
26. Crow, T. J. Meaning of structural changes in the brain in schizophrenia. In: Kales, A.; Stefanis, C. N.; Talbott, J. A., eds. Recent advances in schizophrenia. Springer: New York; 1990:81-94.
27. Crow, T. J.; Cross, A. J.; Johnstone, E. C.; Longden, A.; Owen, F.; Ridley, R. M. Time course of the antipsychotic effect in schizophrenia and some changes in postmortem brain and their relation to neuroleptic medication. Adv. Biochem. Psychopharmacol. 24:495-503; 1980.
28. Crow, T. J.; Mitchell, W. S. Subjective age in chronic schizophrenia: Evidence for a sub-group of patients with defective learning capacity? Br. J. Psychiatry 126:360-363; 1975.
29. Cutting, J. C. The psychology of schizophrenia. Edinburgh: Churchill Livingstone; 1985.
30. Dahl, M. A singular distortion of temporal orientation. Am. J. Psychiatry 115:146-149; 1958.
31. De Leon, J.; Verghese, C.; Stanilla, J. K.; Lawrence, T.; Simpson, G. M. Treatment of polydipsia and hyponatremia in psychiatric patients. Can clozapine be a new option? Neuropsychopharmacology 12:133-138; 1995.
32. Dement, W.; Kleitman, N. Cyclic variations in EEG during sleep and their relation to eye movement, body motility and dreaming. EEG Clin. Neurophysiol. 9:673-690; 1957.
33. Dement, W.; Kleitman, N. The relation of eye movements during sleep to dream activity: An objective method for the study of dreaming. J. Exp. Psychol. 53:339-346; 1957.
34. De Vries, G. J.; Crenshaw, B. J.; Al-Shamma, H. A. Gonadal steroid modulation of vasopressin pathways. Ann. NY Acad. Sci. 652:387-396; 1992.
35. De Wied, D.; Elands, J.; Kovacs, G. Interactive effects of neurohypohyseal neuropeptides with receptor antagonists on passive avoidance behavior: Mediation by a cerebral neurohypophyseal hormone receptor? Proc. Nat. Acad. Sci. USA 88:1494-1498; 1991.
36. Domhoff, G. W. Finding meaning in dreams: A quantitative approach. New York: Plenum Press; 1996.
37. Ehrenteil, O. F.; Jenney, P. B. Does time stand still for some psychotics? Arch. Gen. Psychiatry 3:1-3; 1960.
38. Elliott, R.; Sahakian, B. J. The neuropsychology of schizophrenia: Relations with clinical and neurobiological dimensions. Psychol. Med. 25:581-594; 1995.
39. Ellis, H. D.; Luauté, J-P.; Retterstøl, N. Delusional misidentification syndromes. Psychopathology 27:117-120; 1994.
40. Ellison, G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res. Rev. 19:223-239; 1994.
41. Factor, S. A.; Molho, E. S.; Podskalny, G. D.; Brown, D. Parkinson's disease: Drug-induced psychiatric states. Adv. Neurol. 65:115-138; 1995.
42. Fanget, F.; Claustrat, B.; Daley, J.; Brun, J.; Terra, J. L.; Marie-Cardine, M.; Guyotat, J. Nocturnal plasma melatonin levels in schizophrenic patients. Biol. Psychiatry 25:499-501; 1989.
43. Fernstrom, J. D.; Fisher, L. A.; Cusak, B. M.; Gillis, M. A. Radioimmunologic detection and measurement of nonapeptides in the pineal gland. Endocrinology 106:243-251; 1980.
44. Ferrier, I. N.; Arendt, J.; Johnstone, E. C. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight. Clin. Endocrinol. 17:181-187; 1982.
45. Fishbein, W.; Gutwein, B. M. Paradoxical sleep and a theory of long-term memory. In: Fishbein, W., ed. Sleep, dreams and memory. Lancaster: MTP Press; 1981:183-203.
46. Flaum, M.; Schultz, S. K. The core symptoms of schizophrenia. Ann. Med. 28:525-531; 1996.
47. Foulkes, D. Dream reports from different states of sleep. J. Abnorm. Soc. Psychol. 65:14-25; 1962.
48. Fuller, M. A.; Jurjus, G.; Kwon, K.; Konicki, P. E.; Jaskiw, G. E. Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. J. Clin. Psychopharmacol. 16:329-332; 1996.
49. Gillin, J. C.; Wyatt, R. J. Schizophrenia: Perchance a dream. Int. Rev. Neurobiol. 17:297-342; 1975.
50. Gold, J. M.; Randolph, C.; Carpenter, C. J.; Goldberg, T. E.; Weinberger, D. R. Forms of memory failure in schizophrenia. J. Abnorm. Psychol. 101:487-494; 1992.
51. Goldberg, T. E.; Weinberger, D. R.; Pliskin, N. H.; Berman, K. F.; Podd, M. H. Recall memory deficit in schizophrenia. A possible manifestation of prefrontal dysfunction. Schizophrenia Res. 2:251-257; 1989.
52. Goldstein, R. A GABAergic habenulo-raphe pathway mediation of the hypnogenic effects of vasotocin in cat. Neuroscience 10:941-945; 1983.
53. Goldstein, R. Vasotocin-like activity of cerebrospinal fluid induced by habenular lesions in cats. Neuropeptides 6:303-310; 1985.
54. Goldstein, R. Habenular nuclei specifically bind synthetic arginine-vasotocin. Rev. Roum. Med. Endocrinol. 27:237-239; 1989.
55. Goodenough, D. Dream recall: History and current status of the field. In: Ellman, S.; Antrobus, J., eds. The mind in sleep. New York: Wiley; 1991:143-171.
56. Gordon, C. M.; Carey, M. P. Penile tumescence monitoring during morning naps to assess male erectile functioning: An initial study of healthy men of varied ages. Arch. Sex. Behav. 24:291-307; 1995.
57. Greenberg, R. Dreams and REM sleep - an integrative approach. In: Fishbein, W., ed. Sleep, dreams and memory. Lancaster: MTP Press; 1981:125-133.
58. Greenberg, R.; Katz, H.; Schwartz, W.; Pearlman, C. A research-based reconsideration of the psychoanalytic theory of dreaming. J. Am. Psychoanal. Assoc. 40:531-550; 1992.
59. Guerrero, J.; Crocq, M. A. Sleep disorders in the elderly: Depression and post-traumatic stress disorder. J. Psychosom. Res. 38 Suppl. 1:141-150; 1994.
60. Hall, C. S.; Van de Castle, R. L. The content analysis of dreams. New York: Appleton-Century-Crofts; 1966.
61. Hebb, D. O. The organization of behavior, a neuropsychological theory. New York: Wiley; 1949.
62. Henderson, D. C.; Goff, D. C. Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biol. Psychiatry 36:768-770; 1994.
63. Illowsky, B. P.; Kirch, D. G. Polydipsia and hyponatremia in psychiatric patients. Am. J. Psychiatry 145:675-683; 1988.
64. Iwamuro, S.; Hayashi, H.; Kikuyama, S. An additional arginine-vasotocin-related peptide, vasotocinyl-Gly-Lys, In: Xenopus neurohypophysis. Biochim. Biophys. Acta 1176:143-147; 1993.
65. Johnstone, E. C.; Owens, D. G.; Bydder, G. M.; Colter, N.; Crow, T. J.; Frith, C. D. The spectrum of structural brain changes in schizophrenia: Age of onset as a predictor of cognitive and clinical impairments and their cerebral correlates. Psychol. Med. 19:91-103; 1989.
66. Jung, C. G. The Psychology of Dementia Praecox. New York: Journal of Nervous and Mental Disease Publishing Co.; 1936.
67. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45:789-796; 1988.
68. Klein, D. F.; Gittelman, R.; Quitkin, F.; Rifkin, A. Diagnosis and drug treatment of psychiatric disorders: Adults and children, 2nd ed. Baltimore: Williams and Wilkins; 1980.
69. Lanzkron, J.; Wolfson, W. Prognostic value of perceptual distortion of temporal orientation in chronic schizophrenics. Am. J. Psychiatry 114:744-746; 1958.
70. Leadbetter, R. A.; Shutty, M. S. Jr. Differential effects of neuroleptic and clozapine on polydipsia and intermittent hyponatremia. J. Clin. Psychiatry 55 Suppl B: 110-113; 1994.
71. Lee, H. S.; Kwon, K. Y.; Alphs, L. D.; Meltzer, H. Y. Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. J. Clin. Psychopharmacol. 11:222-223; 1991.
72. Lehmann, H. E. Schizophrenia: Clinical features. In: Kaplan, H. I.; Freedman, A. M.; Sadock, B. J., eds. Comprehensive textbook of psychiatry, 3rd ed., vol. 2. Baltimore & London: Williams and Wilkins; 1980:1153-1192.
73. Liberzon, I.; Chalmers, D.; Mansour, A.; Lopez, J. F.; Watson, S. J.; Young, E. A. Glucocorticoid regulation of hippocampal oxytocin receptor binding. Brain Res. 650:317-322; 1994.
74. Lipton, A. M.; Cancro, R. Schizophrenia: Clinical features. In: Kaplan, H. I.; Sadock, B. J., eds. Comprehensive textbook of psychiatry, 6th ed., vol. 2. Baltimore and London: Williams and Wilkins; 1995:968-987.
75. Liu, B.; Burbach, P. H. Characterization of vasopressin and oxytocin immunoreactivity in the sheep and rat pineal gland: Absence of vasotocin and detection of a vasopressin-like peptide. Peptides 8:7-11; 1987.
76. Lyster, C.; Miller, A. L.; Seidel, D.; Kavanagh, J. Polydipsia and clozapine. Hosp. Community Psychiatry 45:610-611; 1994.
77. McCarley, R. W.; Hoffman, E. A. REM-sleep dreams and the activation-synthesis hypothesis. Am. J. Psychiatry 138:904-912; 1981.
78. 14C]deoxyglucose. In: Iversen, L. L.; Iversen, S. D.; Snyder, S. H., eds. Handbook of psychopharmacology, vol. 15. New York: Plenum Press; 1982:321-410.
79. McKay, A. P.; McKenna, P. J.; Bentham, P.; Mortimer, A. M.; Holbery, A.; Hodges, J. R. Semantic memory is impaired in schizophrenia. Biol. Psychiatry 39:929-937; 1996.
80. McKenna, P. J. Schizophrenia and related syndromes. Oxford: Oxford University Press; 1994.
81. McKenna, P. J.; Tamlyn, D.; Lund, C. E.; Mortimer, A. M.; Hammond, S.; Baddeley, A. D. Amnesic syndrome in schizophrenia. Psychol. Med. 20:967-972; 1990.
82. McNulty, J. A.; Prechel, M. M. Circannual analysis of pineal gland indoles and vasotocin-like immunoreactivity in male rats kept on constant photoschedules and temperature. Biol. Signals 1:150-159; 1992.
83. Meltzer, H. Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bull. 18:515-542; 1992.
84. Meltzer, H. Y.; Bastani, B.; Kwon, K. Y.; Ramirez, L. F.; Burnett, S.; Sharpe, J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I: Preliminary report. Psychopharmacology 99:S68-S72; 1989.
85. Michelson, M. A note on age confusion in psychosis. Psychiatr. Q. 42:331-338; 1968.
86. Monteleone, P.; Maj, M.; Fusco, M.; Kemali, D.; Reiter, R. J. Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophrenia Res. 7:77-84; 1992.
87. Munn, N. A. Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment. J. Clin. Psychiatry 54: 439-440; 1993.
88. Negro-Vilar, A.; Sanchez-Franco, F.; Kwiatkowski, M.; Samson, W. K. Failure to detect radioimmunoassayable arginine vasotocin in mammalian pineals. Brain Res. Bull. 4:789-792; 1979.
89. Noteborn, H. P. J. M.; Reinharz, A. C.; Pévet, P.; Ebels, I.; Salemink, C. A. Neurohypophyseal hormone-like peptides in the ovine pineal gland using reverse-phase liquid chromatography and radioimmunoassay. Peptides 9:455-462; 1988.
90. Odom-White, A.; de Leon, J.; Stanilla, J.; Cloud, B. S.; Simpson, G. M. Misidentification syndromes in schizophrenia: Case reviews with implications for classification and prevalence. Aust. New Zealand J. Psychiatry 29:63-68; 1995.
91. 1, modify brain glucose metabolism. Brain Res. 327:390-394; 1985.
92. Pavel, S. Tentative identification of arginine vasotocin in human cerebrospinal fluid. J. Clin. Endocrinol. 31:369-371; 1970.
93. Pavel, S. Evidence for the ependymal origin of arginine vasotocin in the bovine pineal gland. Endocrinology 89:613-614; 1971.
94. Pavel, S. Arginine vasotocin as a pineal hormone. J. Neural Trans. Suppl. 13:135-155; 1978.
95. Pavel, S.; Goldstein, R. Further evidence that melatonin represents the releasing hormone for pineal vasotocin. J. Endocrinol. 82:1-6; 1979.
96. Pavel, S.; Goldstein, R.; Calb, M. Vasotocin content in the pineal gland of foetal, newborn and adult male rats. J. Endocrinol. 66:283-284; 1975.
97. Pavel, S.; Goldstein, R.; Ghinea, E.; Calb, M. Chromatographic evidence for vasotocin biosynthesis by cultured pineal ependymal cells from rat fetuses. Endocrinology 100:205-208; 1977.
98. Pavel, S.; Goldstein, R.; Popoviciu, L.; Corfariu, O.; Földes, A.; Farkas, E. Pineal vasotocin: REM sleep dependent release into cerebrospinal fluid of man. Waking Sleeping 3:347-352; 1979.
99. Pearlman, C. A. Rat models of the adaptive function of REM sleep. In: Fishbein, W., ed. Sleep, dreams and memory. Lancaster: MTP Press; 1981:37-46.
100. Peroutka, S. J.; Snyder, S. H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 137:1518-1522; 1980.
101. Pevet, P.; Dogterom, F.; Buijs, R. M.; Reinharz, A. Is it the vasotocin or a vasotocin-like peptide which is present in the mammalian pineal and subcommissural organ? J. Endocrinol. 80:49P; 1979.
102. Pévet, P.; Neascu, C.; Holder, F. C.; Reinharz, A.; Dogterom, F.; Buijs, R. M.; Guerne, J. M.; Vivien-Roels, B. The vasotocin-like biological activity present in the bovine pineal is due to a compound different from vasotocin. J. Neural Trans. 51:295-302; 1981.
103. Phillipson, O. T.; Pycock, C. J. Dopamine neurons of the ventral tegmentum project to both medial and lateral habenula. Exp. Brain Res. 45:89-94; 1982.
104. Prechel, M. M.; Audhya, T. K.; Schlesinger, D. H. A seasonal variation in arginine vasotocin immunoactivity in rat pineal glands. Endocrinology 112:1474-1478; 1983.
105. Rechtschaffen, A.; Schulsinger, F.; Mednick, S. Schizophrenia and physiological indices of dreaming. Arch. Gen. Psychiatry 10:89-93; 1964.
106. Richelson, E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J. Clin. Psychiatry 45:331-336; 1984.
107. Robbins, P. R.; Houshi, F. Some observations on recurrent dreams. Bull. Menninger Clin. 47:262-265; 1983.
108. Roberts, G. The origins of delusion. Br. J. Psychiatry 161:298-308; 1992.
109. Room, P.; Tielemans, A. J.; De Boer, T.; Van Delft, A. M.; Tonnaer, J. A. The effect of the potential antipsychotic ORG 5222 on local cerebral glucose utilization in freely moving rats. Eur. J. Pharmacol. 205:233-240; 1991.
110. Rosenbloom, A. A.; Fisher, D. A. Radioimmunoassayable AVT and AVP in adult mammalian brain tissue: Comparison of normal and Brattleboro rats. Neuroendocrinology 17:354-361; 1975.
111. Rouille, Y.; Michel, G.; Chauvet, M. T.; Chauvet, J.; Acher, R. Hydrins, new hydro-osmotic neurohypophyseal peptides: Osmoregulatory adaptation in amphibians through vasotocin precursor processing. Proc. Nat. Acad. Sci. USA 86:5272-5275; 1989.
112. Rouille, Y.; Ouedraogo, J.; Chauvet, J.; Acher, R. Distinct hydroosmotic receptors for the neurohypophyseal peptides vasotocin and hydrins in the frog Rana esculenta. Neuropeptides 29:301-305; 1995.
113. Sandyk, R. Pineal calcification and subtypes of tardive dyskinesia. Int. J. Neurosci. 53:223-229; 1990.
114. Sandyk, R. Pineal and habenula calcification in schizophrenia. Int. J. Neurosci. 67:19-30; 1992.
115. Sawyer, W. H. Increased water permeability of the bullfrog (Rana catesbiana) bladder in vitro in response to synthetic oxytocin and arginine vasotocin and to neurohypophyseal extracts from non-mammalian vertebrates. Endocrinology 66:112-120; 1960.
116. Scherbaum, N. Psychiatrie and Psychoanalyse - Eugen Bleulers "Dementia praecox oder Gruppe der Schizophrenien" (1911). Fortschr. Neurol. Psychiatr. 60:289-295; 1992.
117. Schmidt, M. H.; Valatx, J. L.; Schmidt, H. S.; Wauquier, A.; Jouvet, M. Experimental evidence of penile erections during paradoxical sleep in the rat. NeuroReport 5:561-564; 1994.
118. Sebens, J. B.; Koch, T.; Ter-Horst, G. J.; Korf, J. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur. J. Pharmacol. 273:175-182; 1995.
119. Seeman, P.; Lee, T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219; 1975.
120. Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719; 1976.
121. Sims, A. Symptoms in the mind: An introduction to descriptive psychopathology. London: Baillière Tindall; 1988.
122. Skagerberg, G.; Lindvall, O.; Bjorklund, A. Origin, course and termination of the mesohabenular dopamine pathway in the rat. Brain Res. 307:99-108; 1984.
123. Smith, A.; McIntosh, N. Neurohypophysial peptides in the human fetus: Presence in pituitary extracts of immunoreactive arginine-vasotocin. J. Endocrinol. 99:441-445; 1983.
124. Smith, C. Sleep states, memory processes and synaptic plasticity. Behav. Brain Res. 78:49-56; 1996.
125. Smith, J. W.; Oswald, W. T. Subjective age in chronic schizophrenia. Br. J. Psychiatry 128:100; 1976.
126. Smith, M. E.; Hall, C. S. An investigation of regression in a long series of dreams. J. Gerontol. 19:66-71; 1964.
127. Spear, N. E.; Gordon, W. C. Sleep, dreaming and the retrieval of memories. In: Fishbein, W., ed. Sleep, dreams and memory. Lancaster: MTP Press; 1981:183-203.
128. Spears, N. M.; Leadbetter, R. A.; Shutty, M. S. Clozapine treatment in polydipsia and intermittent hyponatremia. J. Clin. Psychiatry 57: 123-128; 1996.
129. Stevens, M.; Crow, T. J.; Bowman, M. J.; Coles, E. C. Age disorientation in chronic schizophrenia: A constant prevalence of 25% in a chronic mental hospital population. Br. J. Psychiatry 133:130-136; 1978.
130. Strauch, I.; Meier, B. Den Träumen auf der Spur. Bern: Hans Huber; 1992.
131. Tamlyn, D.; McKenna, P. J.; Mortimer, A. M.; Lund, C. E.; Hammond, S.; Baddeley, A. D. Memory impairment in schizophrenia: Its extent, affiliations and neuropsychological character. Psychol. Med. 22:101-115; 1992.
132. Tandon, R.; Shipley, J. E.; Taylor, S.; Greden, J. F.; Eiser, A.; DeQuardo, J.; Goodson, J. Electroencephalographic sleep abnormalities in schizophrenia: Relationship to positive/negative symptoms and prior neuroleptic treatment. Arch. Gen. Psychiatry 49:185-194; 1992.
133. Taylor, J. ed. Selected writings of John Hughlings Jackson, vol. II. New York: Basic Books; 1958.
134. Trenholme, I.; Cartwright, R.; Greenberg, G. Dream dimension differences during a life change. Psychiatry Res. 12:36-45; 1984.
135. Tribollet, E.; Audigier, S.; Dubois-Dauphin, M.; Dreifuss, J. J. Gonadal steroids regulate oxytocin receptors but not vasopressin receptors in the brain of male and female rats: An autoradiographical study. Brain Res. 511:129-140; 1990.
136. Tribollet, E.; Dubois-Dauphin, M.; Dreifuss, J. J. Oxytocin receptors in the central nervous system: Distribution, development and species differences. Ann. NY Acad. Sci. USA 652:29-38; 1992.
137. Uvnäs-Moberg, K.; Alster, P.; Svensson, T. H. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology 109:473-476; 1992.
138. Verghese, C.; De Leon, J.; Simpson, G. M. Neuroendocrine factors influencing polydipsia in psychiatric patients: An hypothesis. Neuropsychopharmacology 9:157-166; 1993.
139. Vieweg, W. V. R.; David, J. J.; Rowe, W. T.; Peach, M. J.; Veldhuis, J. D.; Kaiser, D. L.; Spradlin, W. W. Psychogenic polydipsia and water intoxication - concepts that have failed. Biol. Psychiatry 20: 1308-1320; 1985.
140. Vizsolyi, E.; Perks, A. M. New neurohypophysial principle in foetal mammals. Nature 223:1169-1171; 1969.
141. Walkup, J. A clinically based rule of thumb for classifying delusions. Schizophrenia Bull. 21:323-331; 1995.
142. Weiler, M. A.; Buchsbaum, M. S.; Gillin, J. C.; Tafalla, R.; Bunney, W. E. Jr. Explorations in the relationship of dream sleep to schizophrenia using positron emission tomography. Neuropsychobiology 23:109-118; 1990.
143. White, F. J.; Wang, R. Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057; 1983.
144. Wilson, W. H. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am. J. Psychiatry 153: 951-952; 1996.
145. Zarcone, V. Sleep abnormalities in schizophrenia. In: Kryger, M. H.; Roth, T.; Dement, W. C., eds. Principles and practice of sleep medicine. Philadelphia: W.B. Saunders; 1989:422-423.
146. Zarcone, V. Jr.; Azumi, K.; Dement, W.; Gulevich, G.; Kraemer, H.; Pivik, T. REM phase deprivation and schizophrenia II. Arch. Gen. Psychiatry 32:1431-1436; 1975.